X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (25346) 25346
Newsletter (1373) 1373
Newspaper Article (492) 492
Magazine Article (137) 137
Book Chapter (97) 97
Transcript (52) 52
Book / eBook (9) 9
Book Review (6) 6
Dissertation (6) 6
Report (4) 4
Trade Publication Article (4) 4
Reference (3) 3
Web Resource (2) 2
Conference Proceeding (1) 1
Government Document (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21738) 21738
antiviral agents - therapeutic use (11819) 11819
male (11395) 11395
female (11288) 11288
antiviral agents (10359) 10359
adult (8962) 8962
middle aged (8544) 8544
antiviral agents - adverse effects (7337) 7337
treatment outcome (5465) 5465
health aspects (4834) 4834
hepatitis c, chronic - drug therapy (4728) 4728
drug therapy, combination (4349) 4349
antiviral agents - administration & dosage (4324) 4324
infectious diseases (4323) 4323
hiv (4296) 4296
gastroenterology & hepatology (4183) 4183
drug therapy (4142) 4142
hepatitis c (4012) 4012
aged (3868) 3868
infection (3475) 3475
hiv infections - drug therapy (3434) 3434
therapy (3309) 3309
care and treatment (3296) 3296
risk factors (3173) 3173
pharmacology & pharmacy (3128) 3128
hepatitis c virus (3049) 3049
interferon (2973) 2973
ribavirin (2904) 2904
interferon-alpha - therapeutic use (2857) 2857
immunology (2855) 2855
research (2762) 2762
ribavirin - therapeutic use (2701) 2701
analysis (2609) 2609
hepatitis (2592) 2592
virology (2445) 2445
interferon-alpha - adverse effects (2438) 2438
adolescent (2433) 2433
infections (2423) 2423
hiv infection (2397) 2397
transplantation (2332) 2332
highly active antiretroviral therapy (2310) 2310
animals (2279) 2279
human immunodeficiency virus--hiv (2279) 2279
viral load (2263) 2263
virus diseases (2199) 2199
aids (2131) 2131
hepatitis c - drug therapy (2126) 2126
hepacivirus - genetics (2108) 2108
genotype (2076) 2076
viruses (2051) 2051
recombinant proteins (2031) 2031
retrospective studies (2002) 2002
young adult (1962) 1962
antiviral agents - pharmacology (1893) 1893
antiretroviral therapy (1836) 1836
microbiology (1799) 1799
ribavirin - adverse effects (1795) 1795
medical research (1736) 1736
time factors (1723) 1723
dosage and administration (1713) 1713
virus-infection (1609) 1609
prevention (1600) 1600
patients (1593) 1593
medicine, general & internal (1582) 1582
liver (1546) 1546
medicine & public health (1532) 1532
disease (1520) 1520
polyethylene glycols - therapeutic use (1515) 1515
child (1511) 1511
hiv patients (1489) 1489
hepacivirus - drug effects (1488) 1488
hepatitis b (1476) 1476
mortality (1470) 1470
prospective studies (1464) 1464
hepatitis b, chronic - drug therapy (1458) 1458
medicine (1428) 1428
medicine, experimental (1410) 1410
hiv infections - complications (1383) 1383
clinical trials (1375) 1375
ribavirin - administration & dosage (1362) 1362
antiviral therapy (1347) 1347
efficacy (1342) 1342
antiretroviral drugs (1330) 1330
biological response modifiers (1321) 1321
hepatitis c, chronic - virology (1303) 1303
interferon-alpha - administration & dosage (1296) 1296
anti-hiv agents - therapeutic use (1288) 1288
research article (1284) 1284
complications and side effects (1271) 1271
safety (1249) 1249
surgery (1243) 1243
recurrence (1213) 1213
virus (1175) 1175
anti-hiv agents (1134) 1134
hepatitis c, chronic - complications (1124) 1124
drugs (1121) 1121
cirrhosis (1116) 1116
lamivudine (1114) 1114
usage (1111) 1111
follow-up studies (1090) 1090
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (26299) 26299
Spanish (261) 261
French (258) 258
German (225) 225
Japanese (185) 185
Chinese (151) 151
Russian (70) 70
Polish (44) 44
Italian (37) 37
Korean (33) 33
Dutch (27) 27
Danish (25) 25
Hungarian (23) 23
Portuguese (13) 13
Swedish (12) 12
Czech (10) 10
Norwegian (10) 10
Serbian (8) 8
Croatian (6) 6
Hebrew (5) 5
Finnish (4) 4
Romanian (4) 4
Slovak (4) 4
Ukrainian (3) 3
Arabic (2) 2
Bulgarian (2) 2
Turkish (2) 2
Icelandic (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 10/2018, Volume 30, Issue 10, pp. 1177 - 1186
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2012, Volume 58, Issue 4, pp. 792 - 800
Summary Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug... 
Gastroenterology and Hepatology | Boceprevir | Hepatitis C virus infection | Telaprevir | Pharmacokinetics | Drug interactions | CHRONIC HEPATITIS-C | GASTROENTEROLOGY & HEPATOLOGY | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hepatitis C, Chronic - metabolism | Antiviral Agents - pharmacokinetics | Hypnotics and Sedatives - adverse effects | Humans | Hypnotics and Sedatives - administration & dosage | Drug Interactions | Hypoglycemic Agents - administration & dosage | Drug Therapy, Combination | Immunosuppressive Agents - administration & dosage | Cardiovascular Agents - administration & dosage | Anti-Infective Agents - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Opiate Substitution Treatment - adverse effects | Buprenorphine - administration & dosage | Anti-Infective Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Buprenorphine - adverse effects | Antidepressive Agents - administration & dosage | Immunosuppressive Agents - adverse effects | Methadone - administration & dosage | Methadone - adverse effects | Antidepressive Agents - adverse effects | Cardiovascular Agents - adverse effects | Hypoglycemic Agents - adverse effects | Hepatitis C virus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 3, pp. 216 - 224
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new direct-acting antiviral agents and ribavirin... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
... for approximately 70% of all HCV infections and subgenotype 1b is most predominant in Europe and Eastern Asia. Approved direct-acting antiviral agents (DAAs), telaprevir... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 22, pp. 2134 - 2146
In two trials involving patients with hepatitis C in whom previous treatment with direct-acting antiviral agents failed, treatment for 12 weeks with sofosbuvir, velpatasvir, and voxilaprevir achieved... 
GENOTYPE 1 | MEDICINE, GENERAL & INTERNAL | THERAPY | HEPATITIS-C VIRUS | EFFICACY | PROTEASE INHIBITOR GS-9857 | RESISTANCE | DIRECT-ACTING ANTIVIRALS | OPEN-LABEL | COMBINATION | PHASE-2 TRIAL | Hepatitis C - drug therapy | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Hepatitis C - complications | Sofosbuvir - adverse effects | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Hepatitis C - virology | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Drug Combinations | Care and treatment | Hepatitis C virus | Drug therapy | Patients | Health aspects | Headache | Antiretroviral drugs | Antiviral agents | Proteinase | Clinical trials | Diarrhea | Fatigue | Nausea | Cirrhosis | Hepatitis | Genotypes | Pharmaceuticals | Life Sciences | Human health and pathology
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 368, Issue 20, pp. 1878 - 1887
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
... transcriptase inhibitor (NNRTI), efavirenz, in combination with tenofovir-disoproxil-fumarate and emtricitabine.1–4 However, efavirenz is associated with several adverse... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV
Journal Article